TRDA · Entrada Therapeutics Inc
United States · RS rating 13 · As of 2026-11-03
| Price | 4.72 USD |
|---|---|
| 1-day change | -7.6% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 29 / 18 / 30 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 6 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +11.3% |
| Sales growth Q/Q | -19.5% |
| Distance from 52-week high | +70.6% |
| Market cap (USD) | $490.4M |